Stock screenerAll disclosures →
EDGAR →
ABUS
SetupConviction 98LongHealthcareScan · Tue, Sep 8, 2026Bull flagchannel
ABUS$5.17+0.39%
ResistanceSupportVol 14Vol MA14 6.76M
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
Trade plan
LongReward : Risk0.90Entry
Entry
5.45
Risk
Stop
5.08
-6.9% to stop
Reward
Target 1
5.79
+6.2% to target
Stretch
Target 2
6.12
+12.3% to T2
Risk : reward balance
Risk to stopReward to target
Levels are derived from the pattern's structure (resistance, support and ATR) — a mechanical plan, not financial advice. Size positions to your own risk tolerance.
Price5.17
Change+0.39%
Gap-1.36%
Rel volume3.19×
Avg volume5.14M
Avg $ vol26.3M
SMA 204.98
SMA 504.76
SMA 2004.49
Price vs 50+8.52%
Price vs 200+15.05%
MA stackbullish
50/200 cross—
Supertrendup · 4.72
RSI (14)64
MACD hist0.00
MACD cross—
Stoch %K / %D61 / 61
ADX (14)28
+DI / −DI31 / 15
RSI divergence—
MACD divergence—
ATR %+2.98%
ADR %3.01%
52w high5.22
52w low3.67
From 52w high-0.96%
Above 52w low+40.87%
New 52w highNo
SqueezeOff
Bollinger width17.97%
%B0.71
Donchian pos72.82%
Donchian high5.45
Donchian low4.42
AVWAP (52w high)5.18
vs AVWAP high-0.21%
AVWAP (52w low)4.64
vs AVWAP low+11.43%
OBV trendUp
Chaikin MF (20)-0.08
Today vs 20d3.19×
Avg vol (14d)6.76M
Avg vol (20d)5.14M
Avg $ vol (20d)26.3M
Market cap—
RS 3m (vs SPY)+16.75%
RS 6m (vs SPY)-0.86%
RS line new highNo
Trend template8/8
Technical rank78.1
1 week+1.77%
1 month+11.66%
3 months+21.93%
6 months+9.53%
1 year+23.10%
YTD+8.39%
P/E-30.36
P/B3.93
P/S72.21
P/FCF-25.66
EPS-0.1700
Div yield—
ROE-12.95%
ROA-12.23%
Debt/Eq0.00
Current81.42
EV/EBITDA—
Gross margin—
Net margin-237.88%
Rev growth128.21%
EPS growth52.09%
Price target—
Target upside—
Analyst rating—
Institutional75.65%
Ent. value997.77M
Revenue1.01M
Net income-5.14M
Gross profit—
Free cash flow-39.64M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out197.54M
Employees19
ListedThu, Jul 26, 2007
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeA+
Conviction98 / 100
Pattern quality92%
Tech rank78.1 / 100
Group rank96 / 100 · Leading
Status laneSetting up
Setup directionLong
Pattern familyChannel
Resistance5.45
Support5.11
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Arbutus Biopharma Corp: Passive 5% stake disclosedSEC EDGAR · Fri, Sep 4, 2026
Congress activity
Disclosed STOCK Act trades in ABUS
No recent disclosed trades by Congress in ABUS. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ABUS · 2 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Sawhney Roger Director · Stock Option (Right to Buy) · 2026-06-08 | Grant | 78.8K | $0 | 2026-06-08 | 2026-06-10 |
Beardsley Robert A Director · Stock Option (Right to Buy) · 2026-06-08 | Grant | 78.8K | $0 | 2026-06-08 | 2026-06-10 |
SEC filings
EDGAR filings in ABUS · 8 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.